OmniSeq News

OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...

read more

OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay

BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...

read more

Launch of Immune Report Card

BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...

read more

Follow Us on Twitter

OmniSeq Advance "All I Want": https://t.co/NwtMmpXspL via @YouTube

Congratulations to @OmniSeq on launching another innovative new #genomic test! Dr. Carl Morrison, here with team at #ASCO18: “You see a lot of studies that show promise with these additional biomarkers, and we’re testing for them right now.” https://t.co/MiUyvBPVo7

Dr. Morrison is so excited about OmniSeq Advance that he breaks out into song! WARNING.. It's a bit catchy!!! #ASCO18

Load More...